Novel Therapies and Combinations Augment Melanoma Treatment Arsenal
Omid Hamid, MD, discusses recent advances in the melanoma treatment landscape and highlights the 21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®.
Omid Hamid, MD, discusses recent advances in the melanoma treatment landscape and highlights the 21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®.
A series of events took John L. Marshall, MD, down his path of becoming a gastrointestinal oncology leader, with a drive that has also solidified…
Felipe Batalini, MD, and Alberto Montero, MD, MBA, CPHQ, detail how allosteric inhibitors targeting PIK3CA such as STX-478 may reduce toxicities seen with orthosteric inhibitors.
Görüşmek dileğiyle… Değerli Meslektaşlarımız, Derin saygılarımızla, sizleri 16-20 Mayıs 2025 tarihleri arasında, Antalya’nın gözde mekanlarından Susesi Otel’de gerçekleştireceğimiz “XX. Ulusal ve III. Uluslararası Türk Kolon…
Researchers sought to determine if HRQoL measures differ with gilteritinib compared with placebo in patients with AML.
An abstract is unavailable.
wednesday, february 26 continental breakfast 7-8 a.m. Keynote Session 4 8-8:30 a.m. Session Chair: Antoni Ribas, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California education…
The director of the Hematology/Oncology Fellowship Training Program at Fox Chase Cancer Center discusses palliative care training for hematology/oncology fellows and highlights a pilot study…
Panelists discuss strategies for patient education and monitoring hyperglycemia with PI3K inhibitors, including pre-treatment screening, baseline assessments, early recognition of adverse events, and supportive care…
Journal of Neuro-Oncology – Pediatric meningiomas (PMs) are rare central nervous system tumors, accounting for 1–5% of all meningiomas, and differ from adult meningiomas in…
Mark A. Lewis, MD, discussed the promise of the ESOPEC and TRANSMET trials and the need for their further investigation.